TRDA
Entrada Therapeutics Inc
NASDAQ · Biotechnology
$10.60
+0.53 (+5.26%)
Open$10.30
Previous Close$10.07
Day High$10.71
Day Low$10.19
52W High$14.02
52W Low$4.93
Volume—
Avg Volume269.1K
Market Cap405.12M
P/E Ratio—
EPS$-2.50
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+70.2% upside
Current
$10.60
$10.60
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 206.54M | 42.90M | 41.05M |
| Net Income | 64.31M | 8.98M | 10.98M |
| Profit Margin | 31.1% | 20.9% | 26.8% |
| EBITDA | 49.76M | 15.57M | 16.71M |
| Free Cash Flow | — | 11.03M | 8.57M |
| Rev Growth | — | +8.9% | +15.8% |
| Debt/Equity | — | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |